Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

The Economics of Genomic Medicine

The Economics of Genomic Medicine VIEWPOINT Insights From the IOM Roundtable on Translating Genomic-Based Research for Health notably targeting the accuracy of sequencing and variant in- W. Gregory Feero, MD, PhD terpretation. To date, little attention has been given to de- Catherine Wicklund, MS, CGC veloping an understanding of the range of economic fac- David L. Veenstra, PharmD, PhD tors beyond the cost of sequencing technology, interpretation, and data storage that will affect the scope of adoption of ge- HE RECENT EXPONENTIAL DECLINE IN THE COST OF SE- nome sequencing technologies in health care. quencing human genomes to within an order of mag- Consideration of the possibility that health care re- nitude of $1000 has led to increased use of this tech- sources will decline and the relatively low levels of US fed- Tnology in a variety of research and clinical settings. eral government funding for genomic translational re- Examples of clinical sequencing success stories for diag- search in comparison to funding for basic preclinical science nosing rare conditions are increasingly common and suggest a need to focus on those economic issues most press- sequencing of tumor samples is being performed in many ing and tractable to study. To this end, the Institute of http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

The Economics of Genomic Medicine

Feero, W. Gregory; Wicklund, Catherine; Veenstra, David L.
JAMA , Volume 309 (12) – Mar 27, 2013
Download PDF
2 pages

Loading next page...
 
/lp/american-medical-association/the-economics-of-genomic-medicine-1bYvRwmjWQ
Publisher
American Medical Association
Copyright
Copyright 2013 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2013.113
pmid
23532238
Publisher site
See Article on Publisher Site

Abstract

VIEWPOINT Insights From the IOM Roundtable on Translating Genomic-Based Research for Health notably targeting the accuracy of sequencing and variant in- W. Gregory Feero, MD, PhD terpretation. To date, little attention has been given to de- Catherine Wicklund, MS, CGC veloping an understanding of the range of economic fac- David L. Veenstra, PharmD, PhD tors beyond the cost of sequencing technology, interpretation, and data storage that will affect the scope of adoption of ge- HE RECENT EXPONENTIAL DECLINE IN THE COST OF SE- nome sequencing technologies in health care. quencing human genomes to within an order of mag- Consideration of the possibility that health care re- nitude of $1000 has led to increased use of this tech- sources will decline and the relatively low levels of US fed- Tnology in a variety of research and clinical settings. eral government funding for genomic translational re- Examples of clinical sequencing success stories for diag- search in comparison to funding for basic preclinical science nosing rare conditions are increasingly common and suggest a need to focus on those economic issues most press- sequencing of tumor samples is being performed in many ing and tractable to study. To this end, the Institute of

Journal

JAMA – American Medical Association

Published: Mar 27, 2013

References

  • In treatment for leukemia, glimpses of the future.
    Kolata, G
  • NIH seeks proposals to study genomic sequencing in newborn period.
  • Carrier testing for severe childhood recessive diseases by next-generation sequencing.
    Bell, CJ; Dinwiddie, DL; Miller, NA
  • Human genome sequencing in health and disease.
    Gonzaga-Jauregui, C; Lupski, JR; Gibbs, RA
  • An unwelcome side effect of direct-to-consumer personal genome testing: raiding the medical commons.
    McGuire, AL; Burke, W
  • The economics of genomic medicine: workshop summary, 2013: National Academies Press.
  • Determinants and consequences of personalized health care and prevention (U01).